EGFR and sarcoma: Prominent pathway alterations, such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), cell cycle protein-dependent kinases 4 and 6 (CDK4/6), and rat sarcoma (RAS) pathways, have been observed.